PPHVanEck Pharmaceutical ETF

Grow my money14y track recordRanked #396 of 2,960 in this goal

Seeks to replicate the price and yield performance of the MVIS US Listed Pharmaceutical 25 Index.

By VanEck · Launched 2011

Annual Cost

0.36%

#1,826 of 5,562 · low cost

Fund Size

$942M

#1,145 of 5,562 · large

Return (1Y)Goal

+18.9%

Track Record

14 years

#951 of 5,562 · established

Performance

Total-return NAV · USD

Growth of $10,000

$12,291+22.9%

Total-return NAV, USD. Net of fund fees, before tax.

Classification

How Beacon categorizes this fund

Asset class

Equity

Region

North america

Cap

Multi cap

Strategy

Index tracking

Sector

Health care

Focus

Pharmaceuticals

Index tracked

MVIS US Listed Pharmaceutical 25 Index

What it actually holds

By weight

Concentration

Top 10 holdings = 74.1% of fundconcentrated

Eli Lilly & Co

20.8%

Novartis AG

10.0%

Merck & Co Inc

8.9%

Novo Nordisk A/S

6.4%

State Street Global Advisors

5.6%

Pfizer Inc

4.6%

Bristol-Myers Squibb Co

4.6%

AbbVie Inc

4.4%

GSK PLC

4.4%

McKesson Corp

4.4%

Asset allocation

Stocks

100.0%

By sector

Healthcare

100.0%

Risk profile

Last 12 months · Sharpe & Sortino need 3+ years

Volatility (1Y)

17.6%Moderate

Year-on-year price swings

Max drawdown

-29.7%Moderate

Worst peak-to-trough loss

Sharpe (3Y)

0.58Decent risk-adjusted returns

Sortino (3Y)

0.84Moderate downside risk

Where to buy

Listing

Exchange: NASDAQ Global Select Market

Full fund details

Objective: Seeks to replicate the price and yield performance of the MVIS US Listed Pharmaceutical 25 Index.
Strategy: Invests primarily in securities that comprise the Pharmaceutical Index, which includes U.S. exchange-listed companies in the pharmaceutical industry. The Fund does not seek to outperform the Index.
Inception date: December 20, 2011
Fund family: VanEck